“Drug giving hope to Alzheimer’s sufferers | 60 Minutes Australia“
Disclaimer: Individual results vary, not all patients respond. Additional maintenance doses are necessary. PSE is innovative (“off-label”). Terms of Use
PSE has potential to help Alzheimer’s, but not every patient is a candidate. To determine whether your loved one might qualify, here are a few important things to consider prior to your consultation:
Edward Tobinick M.D., founder of the INR, developed a unique, off-label, method designed to target brain inflammation in Alzheimer’s Disease.
Read the below published, peer-reviewed scientific articles for a more complete scientific explanation of the role of inflammation in the pathobiology of Alzheimer’s disease, and how PSE is designed to work to combat this inflammation to restore cognitive function in Alzheimer’s patients.
Rapid cognitive improvement in Alzheimer’s disease following PSE administration. Edward Tobinick MD, Hyman Gross MD. Journal of Neuroinflammation. 2008 Jan 9;5:2.
Rapid improvement in verbal fluency and aphasia following PSE in Alzheimer’s disease. Edward Tobinick MD, H. Gross MD. BMC Neurology. 2008 Jul 21;8:27.
PSE for treatment of Alzheimer’s disease. Edward Tobinick MD. Current Alzheimer Research. 2007 Dec;4(5):550-2.
Sue Griffin, Ph.D., founder of the Journal of Neuroinflammation, discusses her experience witnessing PSE treatment.Griffin WS. J Neuroinflammation. 2008 Jan 10;5:3.
Tumour necrosis factor modulation for treatment of Alzheimer’s disease: rationale and current evidence. Edward Tobinick MD. CNS Drugs. 2009 Sep 1;23(9):713-25.
PSE for neuroinflammatory disorders. Edward Tobinick MD. Drug Discovery Today. 2009 Feb;14(3-4):168-77.
PSE: a new therapeutic paradigm in neurology. Edward Tobinick MD. Expert Review of Neurotherapeutics. 2010 Jun;10(6):985-1002.
Deciphering the physiology underlying the rapid clinical effects of PSE in Alzheimer’s disease. Edward Tobinick MD. Current Alzheimer Research. 2012 Jan 1; 9(1):99-109.
To read more scientific articles, click here.
Perispinal etanercept is a method of targeting detrimental neuroinflammation using etanercept, a special anti-inflammatory drug, delivered utilizing a novel, non-invasive injection method.
Perispinal etanercept is NOT experimental. Perispinal etanercept has been used to treat more than 5,000 chronic stroke patients since 2010 at the Institute of Neurological Recovery.
No, it is not too late. Neuroinflammation can last for years, or even decades, after brain injury. Life-changing neurological improvements following perispinal etanercept treatment performed weeks, months, years, or even decades after stroke or brain injury are not uncommon.
Referrals are not required. The Institute of Neurological Recovery has received, and welcomes, referrals from neurologists, speech pathologists, physical therapists, occupational therapists, primary care physicians, online stroke groups, and, of course, patients and their family members.
Receive detailed information regarding the Institute’s unique, patented, anti-inflammatory treatment. We currently treat and accept new patients from around the world, even years or decades after stroke or traumatic brain injury.
Complete the form and a member of our team will be in touch shortly.
